Acurx Pharmaceuticals (NASDAQ:ACXP) Releases Earnings Results, Beats Expectations By $0.02 EPS

Acurx Pharmaceuticals (NASDAQ:ACXP) announced its quarterly earnings data on Monday. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.02, Zacks reports.

Acurx Pharmaceuticals Trading Up 3.3 %

NASDAQ ACXP opened at $0.42 on Wednesday. Acurx Pharmaceuticals has a 1-year low of $0.40 and a 1-year high of $3.33. The company has a market capitalization of $8.22 million, a PE ratio of -0.38 and a beta of -1.71. The firm’s fifty day simple moving average is $0.71 and its 200-day simple moving average is $1.27.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Acurx Pharmaceuticals in a research note on Friday, January 10th.

Insider Transactions at Acurx Pharmaceuticals

In other Acurx Pharmaceuticals news, CEO David P. Luci purchased 49,261 shares of the stock in a transaction dated Monday, January 6th. The shares were bought at an average cost of $1.01 per share, with a total value of $49,753.61. Following the completion of the transaction, the chief executive officer now owns 1,097,458 shares in the company, valued at $1,108,432.58. This trade represents a 4.70 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 29.60% of the stock is currently owned by company insiders.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.